Metabolic remodeling in chronic heart failure
- PMID: 23897787
- PMCID: PMC3735968
- DOI: 10.1631/jzus.B1300137
Metabolic remodeling in chronic heart failure
Abstract
Although the management of chronic heart failure (CHF) has made enormous progress over the past decades, CHF is still a tremendous medical and societal burden. Metabolic remodeling might play a crucial role in the pathophysiology of CHF. The characteristics and mechanisms of metabolic remodeling remained unclear, and the main hypothesis might include the changes in the availability of metabolic substrate and the decline of metabolic capability. In the early phases of the disease, metabolism shifts toward carbohydrate utilization from fatty acids (FAs) oxidation. Along with the progress of the disease, the increasing level of the hyperadrenergic state and insulin resistance cause the changes that shift back to a greater FA uptake and oxidation. In addition, a growing body of experimental and clinical evidence suggests that the improvement in the metabolic capability is likely to be more significant than the selection of the substrate.
Conflict of interest statement
This article does not contain any studies with human or animal subjects performed by any of the authors.
Figures
Similar articles
-
[Metabolic therapy for heart failure].Recenti Prog Med. 2014 Jul-Aug;105(7-8):288-94. doi: 10.1701/1574.17114. Recenti Prog Med. 2014. PMID: 25072544 Review. Italian.
-
Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure.Circ Heart Fail. 2010 May;3(3):420-30. doi: 10.1161/CIRCHEARTFAILURE.109.888479. Epub 2010 Feb 22. Circ Heart Fail. 2010. PMID: 20176713
-
Metabolic remodelling of the failing heart: beneficial or detrimental?Cardiovasc Res. 2009 Feb 15;81(3):420-8. doi: 10.1093/cvr/cvn282. Epub 2008 Oct 14. Cardiovasc Res. 2009. PMID: 18854380 Review.
-
Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart.Biochim Biophys Acta. 2011 Jul;1813(7):1333-50. doi: 10.1016/j.bbamcr.2011.01.015. Epub 2011 Jan 20. Biochim Biophys Acta. 2011. PMID: 21256164 Review.
-
Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.Heart. 2011 Sep;97(18):1495-500. doi: 10.1136/hrt.2011.226332. Epub 2011 Jun 23. Heart. 2011. PMID: 21700755 Clinical Trial.
Cited by
-
COUP-TFII revisited: Its role in metabolic gene regulation.Steroids. 2019 Jan;141:63-69. doi: 10.1016/j.steroids.2018.11.013. Epub 2018 Nov 24. Steroids. 2019. PMID: 30481528 Free PMC article. Review.
-
Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.NPJ Precis Oncol. 2018 May 8;2:13. doi: 10.1038/s41698-018-0056-z. eCollection 2018. NPJ Precis Oncol. 2018. PMID: 30202791 Free PMC article. Review.
-
Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction.BMC Cardiovasc Disord. 2016 Nov 17;16(1):225. doi: 10.1186/s12872-016-0399-8. BMC Cardiovasc Disord. 2016. PMID: 27855650 Free PMC article.
-
Chronic Heart Failure: Clinical Implications of Iron Homeostasis Disturbances Revisited.Cureus. 2022 Jan 13;14(1):e21224. doi: 10.7759/cureus.21224. eCollection 2022 Jan. Cureus. 2022. PMID: 35178308 Free PMC article. Review.
-
L-Carnitine, but not coenzyme Q10, enhances the anti-osteoporotic effect of atorvastatin in ovariectomized rats.J Zhejiang Univ Sci B. 2016 Jan;17(1):43-53. doi: 10.1631/jzus.B1500065. J Zhejiang Univ Sci B. 2016. PMID: 26739525 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous